Hydrogen Sulfide Donor Potentiates Radiotherapy

Hydrogen Sulfide Donor Potentiates Radiotherapy:

Hydrogen sulfide (H₂S) is the last gaseous transmitter identified in mammals, and previous studies have reported disparate conclusions regarding the implication of H₂S in cancer progression. In the present study, we hypothesized that sodium hydrosulfide (NaHS), a fast H₂S-releasing donor, might interfere with the mitochondrial respiratory chain of tumor cells, increase tumor oxygenation, and potentiate the response to irradiation. Using electron paramagnetic resonance (EPR) oximetry, we found a rapid increase in tumor pO₂ after NaHS administration (0.1 mmol/kg) in two human tumor models (breast MDA-MB-231 and cervix SiHa), an effect that was due to a decreased oxygen consumption and an increased tumor perfusion. Tumors irradiated 15 minutes after a single NaHS administration were more sensitive to irradiation compared with those that received irradiation alone (increase in growth delay by 50%). This radiosensitization was due to the oxygen effect, as the increased growth delay was abolished when temporarily clamped tumors were irradiated. In contrast, daily NaHS injection (0.1 mmol/kg/day for 14 days) did not provide any effect on tumor growth in vivo. To understand these paradoxical data, we analyzed the impact of external factors on the cellular response to NaHS. We found that extracellular pH had a dramatic effect on the cell response to NaHS, as the proliferation rate (measured in vitro by BrdU incorporation) was increased at pH = 7.4, but decreased at pH = 6.5. Overall, our study highlights the complex role of environmental components in the response of cancer cells to H₂S and suggests a new approach for the use of H₂S donors in combination with radiotherapy. Mol Cancer Ther; 15(1); 154–61. ©2015 AACR.

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1mPYjFp
via IFTTT